Table 1 Table of salient details of major prospective trials investigating simultaneous integrated boost in breast cancer
Author (year) | N | RCT | Dose fractionation | BED (Gy3) | FU | Local control | Late toxicity |
|---|---|---|---|---|---|---|---|
Franco (2014), Turin, Italy | 82 | No | 45 + 5/20# | 91.67 | 12 | 100 | 0 |
Parjis (2012) Brussels, Belgium | 70 | Yes | 42 + 9/15# | 108.80 | 12 | NA | 25% fibrosis (Gr1) |
Mandal (2017), Delhi, India | 10 | No | 40.5 + 7.5/15# | 99.20 | 24 | 100 | NA |
Shin (2016), New York, USA | 45 | No | 40.5 + 7.5/15# | 99.20 | 36 | 100 | 4% lymphedema (G2), 2% skin retraction (G3) |
De Rose (2016), Milan, Italy | 144 | No | 40.5 + 7.5/15# | 99.20 | 37 | 100 | NA |
Cooper (2016), New York, USA | 400 | Yes | 40.5 + 7.5/15# | 99.20 | 45 | 99% | 5.9% fibrosis (G2) |
Cante (2017), Turin, Italy | 178 | No | 45 + 5/25# | 83.33 | 117 | 97.3 | 7% fibrosis (G2), |